Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Fig. 3

Homologous recombination repair deficiency correlates with ACT chemotherapy benefits. A, C Kaplan-Meier graphs of HRD status on OS (A) and FFI (C). Statistical significance was calculated using the log-rank test. B Conceptual depiction of the TNBC patients undergoing ACT chemotherapy. D Forest plot illustrating the HR (95% CI) for FFI calculated using the multivariate Cox proportional hazard models. HR, hazard ratios; CI, confidence interval. E Distribution of ACT sensitive (light colour) or resistant (dark colour) in patients with HR deficiency (red) and HR proficiency (blue)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us